Friday, July 10, 2026

Drug profile · INN

chlortetracycline hydrochloride

chlortetracycline hydrochloride (AUREOMYCIN) is a bacterial 70s ribosome inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — chlortetracycline hydrochloride
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

chlortetracycline hydrochloride (AUREOMYCIN) is a bacterial 70s ribosome inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN chlortetracycline hydrochloride
Brand AUREOMYCIN
Mechanism Bacterial 70S ribosome inhibitor
Target Bacterial 70S ribosome
Route OPHTHALMIC
Formulation OINTMENT

Mechanism of action

Bacterial 70S ribosome inhibitor

Primary target: Bacterial 70S ribosome

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. azithromycin Bacterial 70S ribosome inhibitor
  2. chloramphenicol Bacterial 70S ribosome inhibitor
  3. clarithromycin Bacterial 70S ribosome inhibitor
  4. clindamycin hydrochloride Bacterial 70S ribosome inhibitor
  5. clindamycin palmitate hydrochloride Bacterial 70S ribosome inhibitor
  6. clindamycin phosphate Bacterial 70S ribosome inhibitor

Frequently asked questions

What is chlortetracycline hydrochloride?

chlortetracycline hydrochloride (AUREOMYCIN) is a bacterial 70s ribosome inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for chlortetracycline hydrochloride?

AUREOMYCIN is a marketed brand name for chlortetracycline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of chlortetracycline hydrochloride?

chlortetracycline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.